Phathom Pharmaceuticals: Funding, Investors & Team (Sep 2026)
A biopharmaceutical business called Phathom Pharmaceuticals is dedicated to changing the way GI (gastrointestinal) disorders associated with acid are treated. We are a group of highly motivated healthcare experts with a mission to meet patients' unmet needs and enhance their quality of life. We try to foster a sense of inclusion and belonging by making sure all views are heard, holding ourselves accountable to be just and equitable, and genuinely supporting the individuals and communities affected by our work. We are seeking self-driven, inventive problem solvers that would enjoy working in a fast-paced start-up environment and advancing our development.
Phathom Pharmaceuticals has raised $622M across 5 funding rounds on record, the most recent an undisclosed round of $130M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Phathom Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Phathom Pharmaceuticals Funding Rounds
Phathom Pharmaceuticals raised $200M in a Post-IPO Debt announced in Sep 2021.
1.2 years later, an undisclosed round of $40.0M was announced in Nov 2022.
6 months later, an undisclosed round of $122M was announced in May 2023.
1.3 years later, an undisclosed round of $130M was announced in Aug 2024.
1.4 years later, an undisclosed round of $130M was announced in Jan 2026.
Phathom Pharmaceuticals Founders and Leadership Team
Contact details for the Phathom Pharmaceuticals team: 1 of 3 have an email address on file.
Start 14-day free trial →Phathom Pharmaceuticals Funding Compared to Other Biotechnology Startups
Phathom Pharmaceuticals' latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Phathom Pharmaceuticals in Biotechnology and Florham Park
Companies Similar to Phathom Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Phathom Pharmaceuticals Funding FAQs
What does Phathom Pharmaceuticals do?
A biopharmaceutical business called Phathom Pharmaceuticals is dedicated to changing the way GI (gastrointestinal) disorders associated with acid are treated. We are a group of highly motivated healthcare experts with a mission to meet patients' unmet needs and enhance their quality of life. We try to foster a sense of inclusion and belonging by making sure all views are heard, holding ourselves accountable to be just and equitable, and genuinely supporting the individuals and communities affected by our work. We are seeking self-driven, inventive problem solvers that would enjoy working in a fast-paced start-up environment and advancing our development.
How much funding has Phathom Pharmaceuticals raised?
Phathom Pharmaceuticals has raised $622M across 5 rounds on record. The most recent is an undisclosed round of $130M announced in Jan 2026.
When did Phathom Pharmaceuticals last raise funding?
Phathom Pharmaceuticals' most recent funding round on record is an undisclosed round of $130M, announced in Jan 2026.
Who founded Phathom Pharmaceuticals?
FundedIQ lists Azmi Nabulsi (Founder), Roger Ulrich (Founder) at Phathom Pharmaceuticals.
Who is the CEO of Phathom Pharmaceuticals?
Terrie Curran is listed as CEO at Phathom Pharmaceuticals.
Where is Phathom Pharmaceuticals headquartered?
Phathom Pharmaceuticals is based in Florham Park, New Jersey, United States.
How many employees does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals is in the 101-250 employee band.
How does Phathom Pharmaceuticals' funding compare to other Biotechnology startups?
Phathom Pharmaceuticals' latest round of $130M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Phathom Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Phathom Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.